EPHA4

Overview

EPHA4 (Ephrin type-A receptor 4) is a receptor tyrosine kinase involved in cell signaling, axon guidance, and angiogenesis. In cancer genomics, it has been identified as a low-frequency but potentially FDA-druggable alteration in hepatocellular carcinoma.

Alterations observed in the corpus

Low-frequency but FDA-druggable alteration in HCC (MAP kinase / RTK pathway) PMID:25822088

Cancer types (linked)

HCC: Identified as a low-frequency alteration in the RTK/RAS/MAP kinase pathway in a comprehensive HCC genomic study PMID:25822088

Co-occurrence and mutual exclusivity

Grouped with BRAF, KRAS, ERBB2, EGFR, KIT, KDR, TEK, and JAK1 as low-frequency druggable RTK/MAPK pathway alterations in HCC PMID:25822088

Therapeutic relevance

Potentially actionable in HCC given the availability of FDA-approved agents targeting this pathway PMID:25822088

Open questions

Specific alteration type (mutation/amplification/fusion) and clinical actionability in HCC require further characterization.

Sources

PMID:25822088

This page was processed by crosslinker on 2026-05-14.